Abstract |
Although vitamin K2 is an inducer of the in vitro differentiation of myeloid leukemic cell lines, its clinical efficacy in the treatment of myelodysplastic syndrome (MDS) is unclear. We administered a vitamin K2 analog, menatetrenone, at 45 mg daily to an 80-year-old woman with MDS ( refractory anemia) heavily dependent on red-cell transfusions. The patient's pancytopenia gradually improved, and she became transfusion-independent after 14 months. Pancytopenia recurred when menatetrenone was discontinued but recovered again with readministration. Administration of menatetrenone at a dose effective in improving osteoporosis may also be useful in restoring hematopoiesis in MDS patients, possibly by way of inducing differentiation.
|
Authors | A Takami, S Nakao, Y Ontachi, H Yamauchi, T Matsuda |
Journal | International journal of hematology
(Int J Hematol)
Vol. 69
Issue 1
Pg. 24-6
(Jan 1999)
ISSN: 0925-5710 [Print] Japan |
PMID | 10641439
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Vitamin K 2
- Vitamin K
- menatetrenone
- Calcifediol
|
Topics |
- Aged
- Aged, 80 and over
- Anemia, Refractory
(complications, drug therapy)
- Apoptosis
(drug effects)
- Calcifediol
(therapeutic use)
- Cell Differentiation
(drug effects)
- Drug Therapy, Combination
- Female
- Humans
- Osteoporosis, Postmenopausal
(complications, drug therapy)
- Vitamin K
(analogs & derivatives, pharmacology, therapeutic use)
- Vitamin K 2
(analogs & derivatives)
|